$INTI
Inhibitor Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040351 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $588.4K $500.0K
YoY Change 38.88% 614.39%
% of Gross Profit
Research & Development $684.9K $260.8K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.273M $759.5K
YoY Change 200.55% 985.24%
Operating Profit -$759.5K
YoY Change 985.24%
Interest Expense $106.0K
YoY Change -3255.06%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.167M -$660.0K
YoY Change -109.4% 749.53%
Income Tax
% Of Pretax Income
Net Earnings -$1.167M -$664.8K
YoY Change -109.47% 755.64%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 172.0M shares 172.0M shares
Diluted Shares Outstanding 172.0M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.840M $9.540M
YoY Change -26.03% 17879.65%
Cash & Equivalents $8.840M $9.538M
Short-Term Investments
Other Short-Term Assets $109.2K $70.00K
YoY Change 357.07% 595.83%
Inventory
Prepaid Expenses $70.07K
Receivables
Other Receivables
Total Short-Term Assets $8.949M $9.608M
YoY Change -25.27% 15122.03%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $8.949M $9.608M
Total Long-Term Assets $0.00 $0.00
Total Assets $8.949M $9.608M
YoY Change -25.27% 15122.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $33.73K $93.15K
YoY Change -76.76% -71.47%
Accrued Expenses $631.4K $63.29K
YoY Change 414.94% 81.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $665.2K $156.4K
YoY Change -2.01% -85.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $3.000M $3.000M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $665.2K $156.4K
Total Long-Term Liabilities $3.000M $3.000M
Total Liabilities $3.665M $3.156M
YoY Change -0.37% -22.78%
SHAREHOLDERS EQUITY
Retained Earnings -$48.78M -$47.61M
YoY Change 6.61% -18.01%
Common Stock $17.20K $54.06M
YoY Change -99.97% 7.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.284M $6.451M
YoY Change
Total Liabilities & Shareholders Equity $8.949M $9.608M
YoY Change -25.27% 15122.03%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.167M -$664.8K
YoY Change -109.47% 755.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$700.3K -$560.0K
YoY Change -105.89% 979.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -700.3K -560.0K
Cash From Investing Activities
Cash From Financing Activities -1.000K 0.000
Net Change In Cash -701.3K -560.0K
YoY Change -105.89% -2092.17%
FREE CASH FLOW
Cash From Operating Activities -$700.3K -$560.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
usd
us-gaap Interest Expense
InterestExpense
usd
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
usd
us-gaap Interest And Other Income
InterestAndOtherIncome
usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
INTI Accrued But Unpaid Dividends
AccruedButUnpaidDividends
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-13467
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0793665
dei Entity Address Address Line1
EntityAddressAddressLine1
4905 South West Shore Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33611-3329
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
864-2562
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
172023545 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9537618 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11951224 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
70071 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23900 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
9607689 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11975124 usd
CY2023Q3 us-gaap Assets
Assets
9607689 usd
CY2022Q4 us-gaap Assets
Assets
11975124 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
93147 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
145161 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
411000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
63293 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122621 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
156440 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
678782 usd
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
3156440 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3678782 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
172023545 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
172023545 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
171793134 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
171793134 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
17202 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
17179 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54046845 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54033084 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47612798 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45753921 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6451249 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9607689 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11975124 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
260765 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
696156 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6150 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
498763 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
69987 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1435557 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
228141 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
759528 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
69987 usd
us-gaap Operating Expenses
OperatingExpenses
2131713 usd
us-gaap Operating Expenses
OperatingExpenses
234291 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-759528 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-69987 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2131713 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-234291 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
7705 usd
us-gaap Interest Expense
InterestExpense
19878 usd
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
94768 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
272836 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-664760 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77692 usd
us-gaap Net Income Loss
NetIncomeLoss
-1858877 usd
us-gaap Net Income Loss
NetIncomeLoss
-254169 usd
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
50411 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
149590 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-664760 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-128103 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1858877 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-403759 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172012404 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172012404 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376858323 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171925360 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
171925360 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376858323 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
12250 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-654521 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7114475 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1534 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-664760 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6451249 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3620846 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-98910 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3769071 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-77567 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3896501 usd
CY2022Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
50411 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-77692 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4024605 usd
us-gaap Net Income Loss
NetIncomeLoss
-1858877 usd
us-gaap Net Income Loss
NetIncomeLoss
-254169 usd
us-gaap Share Based Compensation
ShareBasedCompensation
13784 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
46171 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-18099 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-111342 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
78502 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2002606 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157568 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
180000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
411000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-411000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
180000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2413606 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22432 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11951224 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30626 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9537618 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53058 usd
INTI Accrued But Unpaid Dividends
AccruedButUnpaidDividends
250413 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_z7ioAVgsTyVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zyPducTEPjge">Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
230411 shares
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
411000 usd

Files In Submission

Name View Source Status
inti-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001493152-23-040351-index-headers.html Edgar Link pending
0001493152-23-040351-index.html Edgar Link pending
0001493152-23-040351.txt Edgar Link pending
0001493152-23-040351-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
inti-20230930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
inti-20230930_cal.xml Edgar Link unprocessable
inti-20230930_lab.xml Edgar Link unprocessable
inti-20230930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending